Project description
Laser treatment for glaucoma
Glaucoma is an eye disease caused by damage to the optic nerve and unless treated, it can cause vision loss. Funded by the European Innovation Council, the EyeAccess project is introducing a novel laser treatment for glaucoma. The Eagle™ device is automated, easy to use and can be operated by non-expert personnel, making it accessible to more doctors as a first-line treatment for glaucoma patients. Moreover, the Eagle device, which is CE marked, is a patient-friendly, simple and non-contact procedure which will guarantee patient compliance and expedited application in more patients.
Objective
Our novel laser technology - Direct Selective Laser Trabeculoplasty (DSLT) is an automated laser procedure for accessible primary treatment of glaucoma and ocular hypertension. Our Eagle™ device has the potential to revolutionize glaucoma care as it is non-contact, intuitive, and quick.
The technology is ground-breaking, as the procedure doesn’t require expertise and involves simply pressing a button and delivering treatment in seconds. DSLT technology is poised to achieve widespread acceptance, as it is not limited to glaucoma specialists, or bound to glaucoma medication
compliance. In addition, our technology is supported by promising First-in-Human clinical trial results as well as the expertise and guidance of key opinion leaders in the field of ophthalmology. EIC funding will support BELKIN Laser (re-branded recently as BELKIN Vision) in commercializing
this sight-saving technology by establishing the commercial value chain, market launch, and scale-up.
Fields of science
Programme(s)
Funding Scheme
HORIZON-AG - HORIZON Action Grant Budget-BasedCoordinator
8122214 YAVNE
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.